中性粒细胞外细胞陷,活化血小板和内皮细胞在TAVR后患者的前凝效应
Wei Wu1, Dongxia Tong2, Wei Xia3
1Department of Cardiology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, China (W.W.).
Arteriosclerosis, thrombosis, and vascular biology
|April 3, 2025
概括
中性粒细胞外细胞陷 (NETs) 在过导管大动脉置换 (TAVR) 后有助于高凝血. 阻断NET形成可以预防TAVR患者的血栓性并发症.
科学领域:
- 心血管医学 心血管医学
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 由于严重的大动脉狭窄而接受过导管大动脉置换 (TAVR) 的患者面临高血栓并发症风险.
- 导致TAVR后高凝血的精确机制尚不完全理解.
- 中性细胞细胞外陷 (NETs) 参与了血栓形成,但它们在TAVR后的作用需要澄清.
研究的目的:
- 在一年内,研究在TAVR后的患者中,与或没有穿皮冠状动脉干预,对NETs的前凝作用.
- 在TAVR后的环境中评估NET,血小板和内皮细胞之间的相互作用.
主要方法:
- 使用ELISA量化了NETs,血小板和内皮激活标记物的血水平.
- 通过免疫光学可视化了NET的形成.
- 预凝剂活性通过凝血时间,纤维素和氨酸-抗氨酸 (TAT) 复合物生成试验以及酸丁暴露的流细胞计进行评估.
主要成果:
- 血NET水平在TAVR后显著增加,在3个月达到峰值,特别是在接受皮肤冠状动脉干预的患者中.
- 在TAVR后的中性粒细胞和血表现出增强的NET形成,导致凝血时间缩短,纤维素和TAT生成增加.
- 升高的NET度促进了血小板聚合,并诱导了内皮细胞细胞毒性,将它们转移到一种前凝性表型.
结论:
- NET在TAVR后患者观察到的高凝血状态中起着重要作用.
- 向NET生成为缓解TAVR后人群中血栓性并发症提供了潜在的治疗策略.
相关概念视频
Formation of the Platelet Plug
3.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
3.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
588
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
588
Clot Retraction and Fibrinolysis
3.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.2K
Extrinsic and Intrinsic Pathways of Hemostasis
4.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.6K
Introduction to Hemostasis
4.8K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
4.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
448
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
448


